GLP-1 Receptor Agonists and Eye Safety: Examining the NAION Risk at ADA 2025
Do their associations with nonarteritic anterior ischemic optic neuropathy and other adverse outcomes make these drugs more risky than beneficial?
Read the full articleYou might also wanna read
Large Swedish Study Suggests Low Overall Risk of Sudden Vision Loss with GLP-1 RA Use
A nationwide cohort study found a slightly higher risk for nonarteritic anterior ischemic optic neuropathy (NAION) among users of glucagon-l
U.S. Study Suggests GLP-1 RA Drugs Are Associated with Small Increase in Ischemic Optic Neuropathy
A target trial emulation found that people with type 2 diabetes who start glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy had a s
GLP-1s and Blinding Condition; Cyclosporiasis Source Found? Tylenol-Autism Lawsuits
(MedPage Today) -- Note that some links may require registration or subscription. A cohort study found that diabetes patients taking GLP-1 r
Study Probes Absolute Risk for ION With GLP-1 Agents
In patients with type 2 diabetes, GLP-1 RAs may be associated with a higher incidence of ischemic optic neuropathy than other medications, c
Semaglutide Shows Chondroprotective Effects in Osteoarthritis Through Weight Loss-Independent Metabolic Mechanism
Qin et al. demonstrated the chondroprotective effects of semaglutide in obesity-related osteoarthritis. Mechanistically, these effects are i
Newer Diabetes Drugs, Including GLP-1 Agonists, Tied to Autoimmunity Risk
(MedPage Today) -- Analysis of hundreds of thousands of patient records showed differing risks for autoimmune disorders for new users of the
Comments
Sign in to join the conversation.
No comments yet. Be the first.